Clinical evidence has shown that compared with standard Gem/Cis chemotherapies, anti-PD-L1/PD-1 therapy could hardly induce a higher objective response or bring survival benefit to patients with advanced iCCA (YANG et al. 2022; SPIOTTO M T, ROWLEY D A, SCHREIBER 2004). Here, PDCD1 is linked to infantile convulsions and choreoathetosis.